Table 1.
Summary of histopathological evaluation.
| Evaluation | Result | All Patients n (%) a | Patients with Glioblastoma, Gliosarcoma or Giant Cell Glioblastoma, and IDH1 R132H Negative n (%) a |
|---|---|---|---|
| Diagnosis | Glioblastoma | 116 (92) | 103 (96) |
| Glioma, astrocytoma | 3 (2) | 0 | |
| Glioma, gliosarcoma | 3 (2) | 3 (3) | |
| Glioma, pleomorphic xanthoastrocytoma | 1 (1) | 0 | |
| Protoplasmic astrocytoma | 1 (1) | 0 | |
| Oligoastrocytoma | 1 (1) | 0 | |
| Giant cell glioblastoma | 1 (1) | 1 (1) | |
| Assessment of differentiation | Perinuclear halos | 11 (9) | 7 (7) |
| Fibrillary astrocytoma-like foci | 9 (7) | 6 (6) | |
| Small cell astrocytoma-like foci | 27 (21) | 21 (20) | |
| Polar spongioblastic foci | 0 | 0 | |
| Protoplasmic astrocytoma-like foci | 1 (1) | 0 | |
| Minigemistocytes | 5 (4) | 2 (2) | |
| Classic gemistocytes | 16 (13) | 12 (11) | |
| Giant cells | 16 (13) | 15 (14) | |
| PNET-like | 13 (10) | 11 (10) | |
| Sarcoma-like | 7 (6) | 7 (7) | |
| Microcysts | 24 (19) | 18 (17) | |
| Mucoid degeneration | 11 (9) | 8 (8) | |
| Calcifications | 2 (2) | 2 (2) | |
| Vessel structure | Abnormal number of vessels | 117 (93) | 101 (94) |
| Any endothelial hypertrophy | 124 (100) | 107 (100) | |
| Glomeruloid blood vessel | 69 (56) | 62 (58) | |
| Multi-layering blood vessel | 116 (94) | 103 (96) | |
| Vascular abnormalities | 124 (98) | 107 (100) | |
| Vessel thrombosis | 87 (69) | 80 (75) | |
| Cellular density | Low (like diffuse astrocytoma) | 5 (4) | 5 (5) |
| Medium (like classical glioblastoma) | 100 (79) | 86 (80) | |
| High (like PNET) | 21 (17) | 16 (15) | |
| Tumor necrosis | Yes, with pseudopalisading | 36 (29) | 34 (32) |
| Yes, without pseudopalisading | 72 (57) | 64 (60) | |
| No | 18 (14) | 9 (8) | |
| Mitotic scoring | ≤5 Mitoses (per 10 Highpower fields) | 31 (25) | 24 (23) |
| 6–20 Mitoses (per 10 Highpower fields) | 66 (53) | 59 (56) | |
| >20 Mitoses (per 10 Highpower fields) | 28 (22) | 23 (22) | |
| Nuclear abnormalities | Low (nuclear aspect as in normal glial cells) | 4 (3) | 1 (1) |
| Medium (abnormal nuclear shape) | 92 (73) | 78 (73) | |
| High (bizarre nuclei) | 30 (24) | 28 (26) | |
| CD3 parenchymal lymphocytic infiltrate | ≤1% | 54 (47) | 47 (45) |
| 2–4% | 41 (36) | 40 (38) | |
| ≥5% | 20 (17) | 18 (17) | |
| CD3 perivascular lymphocytic infiltrate | None (≤4 perivascular positive cells per vessel) | 24 (21) | 21 (20) |
| Slight (≥1 vessel with ≥5 and <30 positive perivascular cells) | 43 (37) | 38 (36) | |
| Prominent (≥1 vessel with ≥5 and ≥30 positive perivascular cells) | 48 (42) | 46 (44) | |
| IDH1 R132H | Positive | 8 (7) | 0 |
| Negative | 108 (93) | 107 (100) | |
| Ki67 | ≤5% | 6 (6) | 6 (6) |
| 6–10% | 25 (24) | 23 (24) | |
| 11–20% | 43 (41) | 37 (39) | |
| >20% | 32 (30) | 30 (31) | |
| Glial fibrillary acid protein | Cytoplasm Total Detected (H score > 0) | 124 (100) | 105 (100) |
| Cytoplasm H score Median (25th percentile, 75th percentile) | 140 (70, 210) | 150 (90 210) | |
| pSMAD2 | Cytoplasm Total Detected (H score > 0) | 22 (18) | 18 (18) |
| Cytoplasm H score Median (25th percentile, 75th percentile) | 0 (0, 0) | 0 (0, 0) | |
| Nuclei Total Detected (H score > 0) | 119 (100) | 102 (100) | |
| Nuclei H score Median (25th percentile, 75th percentile) | 100 (70, 160) | 110 (75, 160) |
a The denominator for the percentage calculation is the number of randomized patients with a tumor sample for which an evaluable result was obtained. Percentages are rounded to the nearest integer.